NASDAQ:CYTK - Cytokinetics, Incorporated
$8.08
 $0.13
+1.64%
4:00PM EDT
2019-04-18
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CYTK     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 13   199. 07   233. 87  
42 stocks rank:  4. 27 K 1. 43 K 1. 06 K
# analyst opinions:  6. 00   14. 48   14. 09  

quick ratio:  9. 26   5. 29   1. 92  
current ratio:  9. 36   5. 64   2. 40  

target price low:  10. 00   84. 50   115. 74  
target price avg:  13. 50   110. 73   137. 39  
target price high:  21. 00   136. 41   157. 80  
1-yr high:  10. 19   114. 11   138. 85  
last close:  8. 08   87. 56   116. 78  
50-day avg:  7. 78   95. 43   123. 53  
200-day avg:  7. 62   94. 13   121. 20  
1-yr low:  5. 91   72. 67   98. 41  
volume:  273. 88 K 2. 43 M 4. 85 M
50-day avg volume:  636. 82 K 2. 72 M 4. 97 M
200-day avg volume:  397. 73 K 2. 90 M 4. 58 M

1-day return:  1. 64 % -0. 40 % 0. 07 %
this week return:  -7. 87 % -5. 72 % -4. 11 %
12-wk return:  14. 61 % 1. 78 % -0. 04 %
52-wk return:  10. 32 % 10. 81 % 14. 09 %

enterprise value (EV):  312. 98 M 51. 19 B 117. 96 B
market cap:  447. 46 M 43. 00 B 104. 52 B
EBITDA:  -87. 68 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -3. 57   4. 34   13. 27  
enterprise/revenue (EV/R):  9. 94   68. 16   13. 68  
total revenue:  31. 50 M 10. 61 B 38. 24 B
total debt:  42. 41 M 12. 22 B 16. 66 B
debt/equity:  163. 54   46. 86   89. 46  
net income (common):  -106. 29 M 2. 20 B 4. 21 B

shares outstanding:  55. 37 M 570. 91 M 1. 24 B
shares:  41. 44 M 571. 02 M 1. 23 B
shares short:  3. 14 M 9. 93 M 16. 79 M
shares short prior month:  2. 66 M 9. 96 M 16. 58 M
short ratio:  4. 16   5. 31   3. 30  
total cash/share:  3. 62   11. 13   9. 30  
total cash:  198. 73 M 6. 70 B 7. 10 B
free cash flow:  -75. 33 M 3. 58 B 4. 74 B
operating cash flow:  -101. 22 M 4. 14 B 6. 32 B

book value:  0. 47   12. 76   26. 84  
price/book:  17. 05   3. 08   -1. 74  
gross profits:  31. 50 M 8. 03 B 34. 77 B
operating margins:  -282. 26 % -721. 97 % -88. 82 %
EBITDA margins:  -278. 33 % 10. 94 % 22. 54 %
profit margins:  0. 00 % 7. 81 % 10. 60 %
gross margins:  -182. 96 % 37. 02 % 55. 68 %

1-yr max volatility:  19. 04 % --- ---
1-yr mean volatility:  0. 13 % 0. 03 % 0. 04 %

1-yr EPS:  -1. 95   2. 39   4. 08  
forward EPS:  -1. 78   3. 97   7. 14  
P/E:  -4. 14   13. 59   22. 83  
forward P/E:  -4. 93   -20. 05   14. 49  
PE/G:  0. 27   -1. 46   1. 68  
growth:  -15. 32 % 126. 81 % 29. 29 %
earnings high:  -0. 44   1. 02   1. 63  
earnings avg:  -0. 47   0. 76   1. 51  
earnings low:  -0. 50   0. 47   1. 39  
revenue high:  7. 50 M 2. 68 B 10. 71 B
revenue avg:  6. 86 M 2. 59 B 10. 49 B
revenue low:  5. 41 M 2. 49 B 10. 25 B
return on assets:  -21. 97 % -2. 80 % 5. 29 %
return on equity:  -156. 56 % -18. 52 % 7. 38 %
revenue/share:  0. 58   13. 27   55. 24  

beta (1yr vs S&P500):  1. 61   1. 24   0. 93  
sharpe (1yr):  0. 48   0. 29   0. 60  

held % insiders:  7. 32 % 6. 38 % 3. 38 %
held % institutions:  75. 20 % 78. 60 % 68. 65 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-19 : CYTK
.     + 0.89 =          0.89 :: INITIAL WEIGHT
.  + 102.043 =       102.933 :: inverse volume-to-price addition
.   + 45.427 =        148.36 :: spline projection addition
.    x 3.843 =       570.182 :: 13 weeks' performance factor
.    x 1.029 =       586.888 :: one-year gains+dividend factor
.    x 1.432 =       840.438 :: industry recommendation factor
.    x 1.146 =       962.934 :: EV/R factor
.    x 0.998 =       960.818 :: return on assets factor
.    x 0.984 =       945.775 :: return on equity factor
.    x 2.341 =      2213.597 :: current ratio factor
.    x 1.059 =      2343.765 :: quick ratio factor
.    x 1.114 =       2610.31 :: short ratio factor
.     x 2.32 =      6056.854 :: price-to-book factor
.    x 1.628 =      9863.564 :: debt-to-equity factor
.    x 1.091 =      10763.38 :: 5-day avg > 200-day avg
.    x 1.069 =      11507.79 :: 5-day avg > 50-day avg
.    x 1.021 =     11745.283 :: 50-day avg > 200-day avg
.    x 2.104 =     24708.749 :: P/E weight
.    x 1.387 =     34273.381 :: PE/G factor
.    x 1.594 =     54625.161 :: beta factor
.    x 0.483 =     26390.759 :: sharpe factor
.    x 1.506 =     39746.756 :: target low factor
.    x 1.273 =     50597.872 :: target mean factor
.    x 1.126 =     56996.073 :: target high factor
.    x 1.312 =     74758.807 :: industry 2-weeks return factor
.    x 0.919 =     68688.953 :: "drift" penalty 4 days ago
.    x 0.995 =     68358.871 :: overall "drift" factor
.     x 0.81 =     55341.944 :: largest single-day jump factor
.     x 0.11 =      6081.532 :: low price factor
.      x 1.0 =      6080.552 :: factor hist industry gain for week 15
.   cubeRoot =        18.252 :: reduced to standardize
.    - 21.93 =         0.131 :: add/subtract for performance
.                      0.131 :: FINAL WEIGHT for NASDAQ:CYTK


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org